anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology and orthopedics, and can be used to treat infected tumors of the distal segment of the tibia using a precision individualized articulatory anatomical 3-D endoprosthesis-spacer. The method includes installing a spacer for temporary filling of the joint cavity in the period between resection of the affected bone segment and installing a permanent endoprosthesis. An individualized articulatory anatomical 3-D endoprosthesis-spacer impregnated with an antibiotic is made in accordance with the individual dimensions of the removed bone area and its anatomical shape. Orienting along the anterior edge of the tibia, the spacer is fixed in the tibial canal with bone cement, according to the principle of coaxiality with the topographic landmarks of the bone, in accordance with the individual anatomy. The surface of the spacer is additionally covered with bio-sponges impregnated with gentamicin. After installing the vacuum drainage system, the wound is sutured tightly.EFFECT: method ensures the preservation of the functionality of the area of ​​the removed joint and the prevention of the development of periprosthetic infection due to the installation of a spacer covered with bio-gubers impregnated with gentamicin.1 cl, 6 dwg, 1 ex
Nitrofurantoin or Trimethoprim or Cefalexin. Daily antibiotic prophylaxis: nitrofurantoin 50 mg (or 100 mg dependent on participant weight), or trimethoprim 100 mg, or cefalexin 250 mg.
This study seeks to evaluate the psychometric properties of three substance use screening and brief assessment tools for adolescents against criterion standard of Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) substance use disorder diagnoses in a population of adolescents who receives care at a participating primary care practice; or, for an initial evaluation at a substance use disorders program for youth. The three tools to be tested are the Brief Screener for Tobacco, Alcohol and Drugs (BSTAD); Screening to Brief Intervention (S2BI) screening tool; and the Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Tool. BSTAD and S2BI were developed specifically for use with adolescents and each has been validated in a single trial. These tools use past-year "frequency of use" questions to determine risk level for a substance use disorder. The TAPS tool includes both screening and brief assessments and while it has been studied more extensively in adult primary care patients, its validity with adolescents is not known. For youth, alcohol, marijuana and tobacco use, and particularly early initiation, are associated with greater risk of substance use disorders, use of illicit drugs, misuse of opioids, and opioid use disorders. Thus, identifying and addressing substance use early is an important form of prevention that can be delivered in medical care settings for this age group.
Psoriasis participants will be provided sleeves made from the Lumiton yarn to cover their arms. The participants will be instructed to wear the sleeves made from Lumiton yarn daily for 12 weeks both indoors and outdoors.
814,259. Producing solid drops from molten materials. EASTMAN KODAK CO. March 28, 1956 [April 15, 1955], No. 9641/56. Class 87(2). Uniformly-sized beadlets of a normally solid, fusible, organic material are produced by extruding the material under a pressure between 50 and 250 lb. per square inch, substantially free of unfused material, through capillary bores between 0À001 and 0À015 inches diameter into a gaseous cooling medium in liquid streams of substantially uniform cross-section. The molten material is pumped from a heated tank 10 to extrusion heads 19, each of which comprises a housing 32 with an outlet wall comprising a die plate 34 held in place by a cap 36 with a bayonet coupling. The inlet includes filtering media 40, e.g. cotton wadding, retained by a fine mesh screen 39. Drawn stainless steel capillary tubes form the die orifices 42 which may be of various diameters. As the extruded streams of material descend in a tubular structure 23 they become beadlets, which encounter a stream of cooling gas (air, nigtroen, or carbon dioxide) blown upwards through louvres 27 ; or alternatively in the same direction as the stream. The beadlets are collected through a duct 29 with a gate 30. On its way to the extrusion head the material, impelled by a pump 16, passes through a strainer and filter 15, 18 and regulating valve 21, 22. Typical materials are mineral and vegetable waxes, solid fatty materials e.g. lard, tallow and esters of glycerine, to which may be added stabilizers or antioxidants e.g. butylated hydroxy anisole &c. Numerical examples are given of the formation of beadlets from a mineral microcrystalline wax and from a monoester of glycerine.
Automated diagnosis archetypes based on a complete list of library of medical illnesses are used dynamically to help prioritize health data that is relevant to a physician's medical diagnosis for a patient. A super plurality of diagnoses patient archetypes are narrowed to match a patient profile based on information collected from different sources. Based on dynamic physician's diagnosis, the patient profile is mapped to a subset of plurality of patient archetypes. An automated agent is employed to customize a user interface to emphasize order selections to support eliminating a false positive in the proper subset of the plurality of patient persons, a false negative in the plurality of patient archetypes, or to increase a predicted applicability of a set of patient archetypes to the patient profile. The subset of patient archetypes ranking is updated based on received order results. A confirmed dynamic physician diagnosis is made available.
PURPOSE:Dead cell bodies of a specific Escherishia coli alone or a combination thereof are used as an active ingredient to prepare an anticolibacillary agent, which is inoculated to chicken's cloaca to prevent coli infections. CONSTITUTION:An anticolibacillary agent consisting of dead cell bodies of Escherichia coli O1, O2 or O78 strain alone or their combination is inoculated to chicken's cloaca so that the dose becomes more than 1.0X10<15> cell number to prevent chicken's coli infections. Example of the preparation suitable for inoculation are suspensions of the agent in water, physiological salt solution or PBS or their inactivated or adjuvant treatment products. The ready-to-use suspension is dropped, injected, coated, sprayed by 0.02-0.2ml or chicken's vent is  dripped therewith for administration. EFFECT:Almost completely, coli infections are prevented with no side-effects. No development of resistant Escherishia coli is observed.
Musculoskeletal diseases, such as neck and low back pain, are widespread disorders in many developed countries. Their management is challenging, and it may have mounting socioeconomic burden. Several evidences in the literature demonstrate the efficacy of many therapeutic strategies in the treatment of these conditions, based on pharmacological or surgical interventions. Physical medicine therapies are good alternatives that may have beneficial effects, especially when used as first line of intervention before approaching more expensive pharmacological or invasive medications. The beneficial analgesic effects of Applicatio Epispasticorum of Rubefacenciae (redden skin substances), is known since 1830 as a treatment for pain, cramps, and disorders of the musculoskeletal system. Herbal cataplasms containing rubefacient substances, such as Cayenne pepper (CP), are commonly used as natural medications to treat painful or aching areas in the case of acute or chronic back pain, and rheumatisms. They are also used in pain involving joints caused by osteoarthritis. A galenic preparation composed of rubefacient substances of vegetable origin, which generated vasodilation and increase in blood circulation on the treated areas, was first prescribed in 1909 by Dr. Giuseppe Munari to treat pain of various areas of the locomotive system. He proposed a method based on applications prepared according to his own galenic formula that have become famous all over Italy and Europe. In Vienna and lower Austria, a Munari-like application containing CP and Kaolin powder in mixed proportion, is commonly used to treat musculoskeletal conditions of pain especially of the low back. The research on responses to CPC applications, particularly in combination with other modalities is scarce.

Therefore, the aims of the present study are firstly to evaluate the effects of 10x 20min CP cataplasm application on selected functional and molecular parameters on healthy subjects. Then, the same applications will be used on subjects suffering from low back pain (LBP) - both as a single treatment and in combination with electrical stimulation and massage.
The 5th group will be divided into 3 sub groups 5A, 5B, 5C, who will be screened and recruited to serve as unblinded controls for the 1st and 2nd CHMI at 3 and 24 weeks. They will participate only in the screening and 4 weeks follow up of the 1st and 2nd CHMI assessments. Group 5A (n=2) will be challenged at the time of the 3-week CHMI of Group 2. Group 5B (n=2) will be challenged at the time of the 3-week CHMI of Group 3. Groups 5A and 5B will supplement the 4 NS- injected volunteers as infectivity controls, totaling 6 altogether. Group 5C (n=6) will be challenged at the time of the 24-week CHMI for Groups 3 and 4.
A virtual reality (VR)-based interactive system for a neuro-meditation and neuro-concentration training. The system has a VR device with a display. The display is configured to provide a VR content. The system also includes a neural interface apparatus having a plurality of electrodes, each electrode is configured to receive a bio-signal data from a user, and a computing device having a processor. The computing device communicates with the neural interface apparatus and the VR device. The computing device also continuously receives the bio-signal data from the electrodes. The processor determines a feedback based on the bio-signal data and predetermined values and communicates the feedback to the VR device, the feedback being displayed as the VR content on the display of the VR device.
BACKGROUND: Glioblastoma (GBM) is a highly malignant brain tumor that affects men more often than women. In addition, the former shows a poorer survival prognosis. To date, the reason for this sex-specific aggressiveness remains unclear. Therefore, the aim of this study is to investigate tumor processes that explain these sex differences.
METHODS: This was a retrospective study of GBM patients which was stratified according to sex. A cohort with 73 tumors was analyzed with immunohistochemistry, RNA-seq and RT-qPCR to characterize differences in vascular and immunological profiles. Transcriptomic profiling, gene set enrichment analysis, and pathway enrichment analysis were used for discovering molecular pathways predominant in each group. We further investigated the therapeutic effect of bevacizumab (vascular endothelial growth factor A (VEGFA) blocking antibody) in a retrospective GBM cohort (36 tumors) based on sex differences.
RESULTS: We found that under hypoxic tumor conditions, 2 distinct tumor immuno-angiogenic ecosystems develop linked to sex differences and ESR1 expression is generated. One of these subgroups, which includes male patients with low ESR1 expression, is characterized by vascular fragility associated with the appearance of regions of necrosis and high inflammation (called necroinflamed tumors). This male-specific tumor subtype shows high inflammation related to myeloid-derived suppressor cells infiltration. Using this stratification, we identified a possible group of patients who could respond to bevacizumab (BVZ) and revealed a genetic signature that may find clinical applications as a predictor of those who may benefit most from this treatment.
CONCLUSIONS: This study provides a stratification based on the sexual differences in GBM, which associates the poor prognosis with the presence of immunosuppressive myeloid cells in the necrotic areas. This new stratification could change the current prognosis of GBM and identifies those who respond to BVZ treatment.
This group will be provided with loaded sit to stand strengthening exercises in spastic diplegic children.1 repetition maximum of the load will be provided. Exercise will be conducted 3 times a week for 6 weeks, pre and post session functional strength of lower limb will be measured by performing functional strength tests and physiological cost index will be measured to calculate energy expenditure.
Includes one individual session (60 minutes) led by trained psychologist or nurse of occupational health services. The intervention is based on sleep hygiene guidance.
It is known that complications are more serious than diabetes itself. Thus, constitution, exercise, food, and blood sugar should be managed well, but managing such things is not easy. The most difficult thing is to draw blood by a needle every day to manage blood sugar, and the next is food management. Diabetics have to be very careful about what to eat, so there are foods that can be eaten and foods that cannot be eaten. However, it is difficult to care about what to eat every time. In addition, the hospital tells a diabetic to eat a diabetic diet by making a meal plan. However, it is hard to find a diabetic diet, and it is known that it is difficult to plan a meal plan in detail. Moreover, in addition to the importance of food, when a diabetic goes to get his/her medicine, the hospital also asks if the diabetic steadily performs exercise. Exercise must be performed, but exercising too much causes hypoglycemia. If the hospital is asked how much exercise is appropriate, the hospital recommends walking exercise to fathers who have plantar fasciitis and swimming or cycling to grandmothers who have weak knees. Nevertheless, there is a problem in which recommended exercise is not suitable for a patient. Accordingly, the present invention provides a service that recommended exercise items, exercise time, and the amount of exercise recommended according to a user′s health condition. There are different types of diabetes, such as type 1, type 2, a gestation type, and other types. According to the present invention, a service that provides management of diabetes-related diet and exercise specific to the types of diabetes is suggested.
In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multicentered, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than six days but less than two years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to matched placebo-treated group (3.0%). The average duration of treatment with encainide or flecainide in this study was ten months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarctions) is uncertain. Considering the known proarrhythmic properties of procainamide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of procainamide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.

Blood Dyscrasias:Agranulocytosis, bone marrow depression, neutropenia, hypoplastic anemia and thrombocytopenia in patients receiving procainamide hydrochloride have been reported at a rate of approximately 0.5%. Most of these patients received procainamide within the recommended dosage range. Fatalities have occurred (with approximately 20 25 percent mortality in reported cases of agranulocytosis). Since most of these events have been noted during the first 12 weeks of therapy, it is recommended that complete blood counts including white cell, differential and platelet counts be performed at weekly intervals for the first three months of therapy, and periodically thereafter. Complete blood counts should be performed promptly if the patient develops any signs of infection (such as fever, chills, sore throat or stomatitis), bruising or bleeding. If any of these hematologic disorders are identified, procainamide therapy should be discontinued. Blood counts usually return to normal within one month of discontinuation. Caution should be used in patients with pre-existing marrow failure or cytopenia of any type. (See ADVERSE REACTIONS).
Correlate patient longitudinal study of clinical data and their biopsy data. Investigators will determine DEFA5 levels from endoscopy biopsies from known diverticulitis.
In vitro studies revealed that venlafaxine has virtually no affinity for opiate, benzodiazepine, phencyclidine (PCP), or N-methyl-D-aspartic acid (NMDA) receptors. 

Venlafaxine was not found to have any significant CNS stimulant activity in rodents. In primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability.

Discontinuation effects have been reported in patients receiving venlafaxine (see DOSAGE AND ADMINISTRATION). 

While venlafaxine has not been systematically studied in clinical trials for its potential for abuse, there was no indication of drug seeking behavior in the clinical trials. However, it is not possible to predict on the basis of premarketing experience the extent to which a CNS active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of venlafaxine (e.g., development of tolerance, incrementation of dose, drug seeking behavior).
Chronic interstitial nephritis in agricultural communities (CINAC) is an epidemic of kidney disease affecting specific tropical and subtropical regions worldwide and is characterized by progressive CKD in the absence of traditional risk factors, such as hypertension and diabetes. CINAC prevalence is higher among young, male agricultural workers, but it also affects women, children, and nonagricultural workers in affected areas. Biopsies from patients with CINAC across regions commonly demonstrate tubular injury with lysosomal aggregates, tubulointerstitial inflammation, and fibrosis and variable glomerular changes. Each endemic area holds environmental risk factors and patient/genetic milieus, resulting in uncertainty about the cause(s) of the disease. Currently, there is no specific treatment available for CINAC. We highlight survey findings of Houston-based migrant workers with CINAC and draw similarities between kidney injury phenotype of patients with CINAC and mice treated chronically with paraquat, an herbicide used worldwide. We propose potential pathways and mechanisms for kidney injury in patients with CINAC, which may offer clues for potential therapies.
The patient will be in the supine position. The cephalic hand will make contact with one side of the patient's skull, leaving the sternocleidomastoid muscle between the third and fourth fingers. The caudal hand will make global contact with the patient's skull on the opposite side. The therapist should place his torso on the patient's head, leaving the two forearms aligned with the axis of the patient's spine, as this technique is applied to the axis of the odontoid process of the ax. With neutral flexion-extension the therapist will place the rotation parameter to the opposite side (70-80 degrees) and a small contralateral inclination. Then it will search for the driving barrier with a small axial traction movement. When the driving barrier is found, the thrust should be applied in a helical direction, increasing rotation and traction. It will be applied bilaterally.
The investigators will enroll 308 participants. Half of these will be Gulf War Veterans who meet criteria for CMI, and the other half will be Veterans from other periods of service who also meet criteria for CMI. Each participant will be randomized to either participate in MBSR or aCDSMP (stratified by Gulf War deployment status so there are \~7-8 Gulf War Veterans in each group for every cohort). Measures to collect primary outcome data (pain, fatigue, cognitive failures, patient satisfaction), secondary outcomes, and potential mediators will be administered at four assessments: (1) Baseline; (2) Post-Intervention; (3) at 3-months after the group ended; and (4) at 6-months after the group ended. Sample demographic data (age, gender, race, income, education, etc.) will be collected at baseline only. All study procedures will take place at VA Puget Sound Health Care System in Seattle, WA.
Pazopanib and erlotinib are to be combined at different specified dose levels until an optimally tolerated dose level is identified. Pazopanib, a multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, and -3, PDGFR-alpha and beta, and c-kit and erlotinib, an epidermal growth factor (EGFR) inhibitor, are to be combined in an effort to simultaneously block two tightly woven cell signaling pathways.
###  Adults

The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited. The divided regimen was more effective in controlling trough (pre-dosing) blood pressure than the same dose given as a once-daily regimen. Dosage adjustment should be based on measurement of peak (2-6 hours after dosing) and trough responses. If a once-daily regimen does not give adequate trough response, an increase in dosage or divided administration should be considered. If blood pressure is not controlled with benazepril hydrochloride tablets alone, a diuretic can be added.

Total daily doses above 80 mg have not been evaluated.

Concomitant administration of benazepril hydrochloride tablets with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics can lead to increases of serum potassium (see PRECAUTIONS).

In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally can occur following the initial dose of benazepril hydrochloride tablets. To reduce the likelihood of hypotension, the diuretic should, if possible, be discontinued two to three days prior to beginning therapy with benazepril hydrochloride tablets (see WARNINGS). Then, if blood pressure is not controlled with benazepril hydrochloride tablets alone, diuretic therapy should be resumed.

If the diuretic cannot be discontinued, an initial dose of 5 mg benazepril hydrochloride tablets should be used to avoid excessive hypotension.

###  Pediatrics

In children, doses of benazepril hydrochloride between 0.1 and 0.6 mg/kg once daily have been studied, and doses greater than 0.1 mg/kg were shown to reduce blood pressure (see CLINICAL PHARMACOLOGY, Pharmacodynamics). Based on this, the recommended starting dose of benazepril hydrochloride is 0.2 mg/kg once per day as monotherapy. Doses above 0.6 mg/kg (or in excess of 40 mg daily) have not been studied in pediatric patients.

For pediatric patients who cannot swallow tablets, or for whom the calculated dosage (mg/kg) does not correspond to the available tablet strengths for benazepril hydrochloride tablets, follow the suspension preparation instructions below to administer benazepril hydrochloride tablets as a suspension.

Treatment with benazepril hydrochloride tablets is not advised for children below the age of 6 years (see PRECAUTIONS, Pediatric Use) and in pediatric patients with glomerular filtration rate <30 mL, as there are insufficient data available to support a dosing recommendation in these groups.